Paxlovid in the Treatment of COVID-19 Patients With Uremia
Status:
Not yet recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This study is a single-center, open-label, randomized controlled clinical study to evaluate
the effect of Paxlovid on the virus-negative time and disease progression in uremic patients
infected with SARS-CoV-2 (omicron variants).
This study will enroll maintenance hemodialysis patients infected with SARS-CoV-2 (omicron
variants).
After signing the informed consent form, the qualified subjects will be randomly stratified
1:1 to standard-of-care (SOC) or SOC plus Paxlovid for five days.